跳至主要内容
临床试验/2024-512453-25-00
2024-512453-25-00招募中4 期

Efficacy, tolerability and preferences of per oral or subcutaneous methotrexate in patients with early rheumatoid arthritis – a randomised register based multicentre study

Region Vaesterbotten9 个研究点 分布在 1 个国家目标入组 212 人开始时间: 2024年7月3日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
212
试验地点
9
主要终点
DAS28

研究概览

简要总结

Difference in DAS28 over 12 months of follow-up between patients with newly diagnosed RA randomised to either oral or subcutaneous methotrexat.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • The subject has given written consent to participate in the study
  • Diagnosis of rheumatoid arthritis by rheumatologist fulfilling 2010 Rheumatoid Arthritis Classification Criteria
  • Indication of methotrexate
  • 18-95 years of age
  • Women of Childbearing Capacity (WOCBC) must: a) Comply to use of highly effective contraception methods during the course of the trial. b) Have a negative pregnancy test.
  • Male patients included in the study that have fertile female partners must use adequate contraception within their relationship during the same period of time

排除标准

  • Contraindications for methotrexate
  • Previous treatment with any DMARD within the last five years
  • Known or suspected allergies against methotrexate or any other substance in the given medication
  • Anamnestic information on pregnancy, breastfeeding, or planned pregnancy
  • Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation or inability to answer questionnaire in written Swedish
  • Treatment or disease which, according to the investigator, can affect treatment or study results.
  • Fear of needles leading to not being able to use subcutaneous injections
  • For the study in gut microbiota: Use of antibiotics or probiotics within the last 3 months

结局指标

主要结局

DAS28

DAS28

次要结局

  • Number of swollen joints
  • Number of tender joints
  • HAQ
  • VAS pain
  • VAS general health
  • VAS fatigue
  • Doctor's global assessment
  • Number of individuals remaining on the designated drug (drug retention) including number of individuals prescribed biologic treatment
  • Number of patient´s contact with any health care giver
  • All other medications, including corticosteroids, other csDMARDs, biologics, intraarticular injections as well as change in dosage or administration route of methotrexate
  • ESR
  • CRP
  • Number of AE
  • Patients preferences
  • EQ5D
  • Gutmicrobiota
  • Questions on diet and alcohol consumption

研究者

发起方
Region Vaesterbotten
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Anna Södergren

Scientific

Region Vaesterbotten

研究点 (9)

Loading locations...

相似试验